U.S. markets close in 6 hours 30 minutes

BioMarin doses first patient in Phase 1/2 trial with BMN 190

BioMarin Pharmaceutical announced that it has dosed the first patient in the Phase 1/2 trial for BMN 190, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with neuronal ceroid lipofuscinosis type 2, a form of Batten disease. This is the first time that a patient with Batten Disease has been treated with an enzyme replacement therapy in a clinical trial setting.